Pharmaceutics Department, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz 71345, Iran.
Pharmaceutics Department, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz 71345, Iran; Center for Nanotechnology in Drug Delivery, Shiraz University of Medical Sciences, Shiraz 71345, Iran.
Int J Pharm. 2016 Aug 20;510(1):30-41. doi: 10.1016/j.ijpharm.2016.06.026. Epub 2016 Jun 10.
A novel lipopolymer based system was designed and characterized for cellular delivery of anti-VEGF siRNA in SKBR-3 breast tumor cell line. Polyamidoamine (PAMAM) dendrimers of low generations (G1, G2 and G3) were incorporated into polyethylene glycol (PEG)-stabilized liposomes by following the consecutive steps: (a) synthesis of the cholesterol conjugates (40% molar ratio of cholesterol to primary amines of PAMAM), (b) incorporation of the conjugates in liposome by lipid mixing and (c) microencapsulation of the siRNA using the ethanol drop method. The cholesterol conjugates of PAMAM dendrimers (G1-Chol40%, G2-Chol40% and G3-Chol40%) formed self assembly with low CMC values (<11μg/ml). Not only did G2-Chol40% show the highest lipid mixing among the cholesterol conjugates, but also, had the lowest leakage of encapsulated carboxyfluorescein tracer. Various N(amine))/L(lipid)/P(phosphate) mole ratios were investigated for siRNA condensation by ethidium bromide dye exclusion assay. The optimum N/L/P ratio of 20:33:10 was chosen for microencapsulation of anti-VEGF siRNA by ethanol drop method, showing particle size of 130nm, zeta-potential of +4mV, siRNA loading efficiency and capacity of 96% and 13wt%, and high stability against heparin sulfate (extracellular matrix). TEM shows uniform and discrete oligo- or multi-lamellar vesicular structures. The liposome incorporating G2-Chol40% was successfully internalized into SKBR-3 cells mainly through clathrin-mediated endocytosis, which was able to escape from endosomes and showed a significantly higher sequence-specific inhibition of VEGF expression and cell growth than the respective G2-Chol40%/siRNA dendriplexes. Importantly, the cytotoxicity decreased with incorporation of G2-Chol40% in the liposomes.
一种新型的基于脂多糖的系统被设计并用于 SKBR-3 乳腺癌细胞系中抗 VEGF siRNA 的细胞递送。低代(G1、G2 和 G3)聚酰胺胺(PAMAM)树状大分子通过以下连续步骤被纳入聚乙二醇(PEG)稳定的脂质体中:(a)胆固醇缀合物的合成(胆固醇与 PAMAM 伯胺的摩尔比为 40%),(b)通过脂质混合将缀合物掺入脂质体中,以及(c)使用乙醇滴法微囊化 siRNA。PAMAM 树状大分子的胆固醇缀合物(G1-Chol40%、G2-Chol40%和 G3-Chol40%)形成自组装体,CMC 值较低(<11μg/ml)。不仅 G2-Chol40%在胆固醇缀合物中显示出最高的脂质混合,而且包封的羧基荧光素示踪剂的泄漏率最低。通过溴化乙锭染料排除试验研究了各种 N(胺)/L(脂质)/P(磷酸)摩尔比用于 siRNA 凝聚。选择最佳的 N/L/P 比为 20:33:10,用于通过乙醇滴法微囊化抗 VEGF siRNA,其粒径为 130nm,ζ-电位为+4mV,siRNA 负载效率和载量分别为 96%和 13wt%,并且对肝素硫酸盐(细胞外基质)具有高稳定性。TEM 显示均匀和离散的寡层或多层囊泡结构。成功地将含有 G2-Chol40%的脂质体内化到 SKBR-3 细胞中,主要通过网格蛋白介导的内吞作用,能够从内涵体中逃逸,并显示出比相应的 G2-Chol40%/siRNA 树枝状聚合物更高的序列特异性 VEGF 表达和细胞生长抑制作用。重要的是,随着 G2-Chol40%在脂质体中的掺入,细胞毒性降低。
BMC Biotechnol. 2009-4-23
Pharmaceutics. 2021-6-21
Int J Mol Sci. 2020-1-10
Biotechnol Adv. 2017-9